Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects

Independent Data Monitoring Board to review interim data from approximately 200 initial subjects

Read more at globenewswire.com